profit from every ₹100 of sales.
₹0₹100
Syngene International
₹436.90+0.51% today
-33.2% in 1 year
1-year low ₹346.001-year high ₹660.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹55.45 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Syngene International sold, what it kept, and what it did with the cash.
Sales went from ₹30.8 billion in 2023 to ₹37.4 billion in 2026, with ₹3.17 billion of profit last year.
SalesProfit
Syngene International handed back 9% of the cash it generated last year.
₹504M
Free cash flow 2026₹5.5B
Bought back its own shares–
Paid as dividends₹504M
Cash vs. debt₹2.3B vs. ₹4.6B
Syngene International vs. similar companies
Syngene International grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Syngene International | 55.4× · Expensive | ||
 Thermo Fisher Scientific | 39.9× · Expensive | ||
 Danaher | 45.8× · Expensive | ||
 WuXi AppTec | 26.7× · Fair price | ||
 Lonza Group | No profit yet |
AI analysis
An AI analyst reads Syngene International's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 30,802 | 33,695 | 36,424 | 37,387 | |
| 22,200 | 24,393 | 26,999 | 28,201 | |
| 6,182 | 6,471 | 6,111 | 5,265 | |
| 9,946 | 10,918 | 11,456 | 9,126 | |
| 4,644 | 5,100 | 4,962 | 3,167 | |
| 11.51 | 12.69 | 12.34 | – | |
| 72.1% | 72.4% | 74.1% | 75.4% | |
| 20.1% | 19.2% | 16.8% | 14.1% | |
| 15.1% | 15.1% | 13.6% | 8.5% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 58,310 | 61,516 | 67,959 | 70,547 |
| Cash | 870 | 856 | 3,669 | 2,286 |
| Total debt | 8,152 | 5,552 | 5,779 | 4,584 |
| Total liabilities | 22,130 | 18,939 | 20,691 | 22,156 |
| 36,180 | 42,577 | 47,268 | 48,391 | |
| 404 | 402 | 402 | – | |
| 10.6% | 10.4% | 10.1% | 6.5% | |
| 12.8% | 12.0% | 10.5% | 6.5% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 8,235 | 10,421 | 11,676 | 9,152 | |
| 5,183 | 5,108 | 7,701 | 3,682 | |
| 3,052 | 5,313 | 3,975 | 5,470 | |
| Dividends paid | 401 | 503 | 503 | 504 |
| – | – | – | – | |
| 236 | 5 | 373 | 413 |
Valuation
- 55.4×
- –
- –
- 3.7×
- 4.7×
- 32.1×
- 19.5×
- 3.1%
- 1.8%
- 0.3%
Profitability
- 75.4%
- 14.1%
- 8.5%
- –
- 6.5%
- 9.4%
- –
- –
- –
- –
Growth
- +6.7%
- –
- –
- –
- −0.1%
Financial health
- 0.3×
- 0.09
- –
- 9.4×
- 1.38
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 948
Top 37%of 871
Bottom 20%of 560
Bottom 33%of 868
Top 34%of 985
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
15.9% of its profit
Room to growStretchedMore than it earns: 9.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
36No pass
Philip Fisher
43No pass
Peter Lynch
55No pass
Joel Greenblatt
4No pass
Charlie Munger
44No pass
Terry Smith
43No pass
Questions about Syngene International
Is Syngene International a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Syngene International AI analysis
What does Syngene International do?
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. It is in Diagnostics & Research, based in Bengaluru, India.
Does Syngene International pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 16% of its yearly profit. In 2026 it paid out ₹504 million in dividends.
Is Syngene International stock halal?
Yes. Syngene International passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Syngene International stock done over the past year?
Down 33.2% over the past twelve months, to ₹436.90. It traded between ₹346.00 and ₹660.35 and is 33.8% below its high.
Who are Syngene International's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, WuXi AppTec and Lonza Group. The peers table on this page compares their profit, growth and price with Syngene International's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.